Calming Down PTC Therapeutics Investors’ Concerns. More Good News from Sangamo. AERIE’s Glaucoma Drug NDA

Why Buying Emflaza?
Buying Emflaza, a steroid approved by the FDA for Duchenne muscular dystrophy (DMD) from Marathon Pharmaceuticals invited an intractable headache to PTC Pharmaceuticals’ shareholders and scrutiny by some law makers. The cause of the law makers’ involvement has been the Marathon’s pricing Emflaza at $89,000, but PTCT shareholders had several question marks revolving around the motive for buying this drug in the first place. Here are some details about the story as being unfolded by the law makers’ demands, the shareholders questioning and the firm . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.